We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
DxGen

PERKIN ELMER CORPORATION

PerkinElmer provides detection technologies to detect and identify diseases, imaging technologies to help visualize s... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
24 Feb 2021 - 28 Feb 2021
Virtual Venue
03 Mar 2021 - 05 Mar 2021
Virtual Venue

Biomarker Evaluated for Early Detection of Congenital Heart Disease

By LabMedica International staff writers
Posted on 16 Dec 2020
Print article
Image: The GSP instrument is a high throughput batch analyzer intended for quantitative or qualitative measurement of neonatal screening samples on 96-well microplates (Photo courtesy of PerkinElmer).
Image: The GSP instrument is a high throughput batch analyzer intended for quantitative or qualitative measurement of neonatal screening samples on 96-well microplates (Photo courtesy of PerkinElmer).
Congenital heart disease (CHD) is the most common congenital malformation in humans worldwide. Circulating cardiovascular biomarkers could potentially improve the early detection of CHD, even in asymptomatic newborns.

The amino terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP) test has been used in adults with cardiac failure. Evidence has found that the NT-proBNP test is useful in infants who require neonatal intensive care, children with pulmonary hypertension and cardiomyopathies, and children with various types of CHD.

Pediatricians at the University Teaching Hospital Ryhov (Jönköping, Sweden) and their colleagues prospectively enrolled healthy, term neonates born between July 1, 2018, and May 31, 2019 and compared them against retrospectively identified newborns with CHD born between September 1, 2003, and September 30, 2019. The CHD diagnosis was confirmed by echocardiography. Control newborns were followed-up for a minimum of one year using electronic patient records covering routine checkups and additional medical consultations.

The scientists developed a fully automated immunoassay for NT-proBNP measurement from dried blood spot (DBS) samples. Microtitration strips 96-well format were coated with anti-NT-proBNP mouse monoclonal IgG antibody (HyTest Ltd, Turku, Finland) and the monoclonal tracer antibody (HyTest Ltd) was labeled with europium chelate. The hematocrit in this mix was checked with a Coulter Ac · T diff Hematology Analyzer (Beckman Coulter, Brea, CA, USA). A high throughput batch analyzer (GSP Instrument; PerkinElmer, Waltham, MA, USA) was used for the plate assays.

Performed as early as two days after birth, a dried blood spot (DBS) test for NT-proBNP flagged 71% of the 34 tested babies with known CHD and 68% of the critical CHD cases. Combining the DBS test with pulse oximetry screening improved CHD detection to 82% and detection of critical CHD to 89%. Babies with CHD had a median NT-proBNP level of 17,240 ng/L based on the DBS test. Healthy controls had significantly lower NT-proBNP levels, with a median of 1,900 ng/L. A comparison of DBS and standard screening for NT-proBNP (laboratory analysis on 500 μL of blood in a collection tube containing EDTA as an anticoagulant) found the two tests to be highly correlated and in good agreement.

The authors concluded that the DBS NT-proBNP test discriminated well between healthy newborns and newborns with various types of CHD, including critical lesions. Additional reference values were established for days two to four of life, reflecting the timing of common newborn screening programs. The study was published on December 2, 2020 in the journal JAMA Network Open.

Related Links:
University Teaching Hospital Ryhov
HyTest Ltd
Beckman Coulter
PerkinElmer



Print article

Channels

Molecular Diagnostics

view channel
Image: Blood smear from a P. falciparum culture: several red blood cells have ring stages inside them while close to the center is a schizont and on the left a trophozoite (Photo courtesy of Wikimedia Commons)

Panel of MicroRNAs Differentiates Uncomplicated and Severe Malaria in Children

MicroRNAs (miRNAs), which are rapidly released from damaged tissues into the host fluids, constitute a promising biomarker for the prognosis of severe malaria. MiRNAs comprise a class of about 20 n... Read more

Pathology

view channel
Image: The Leica Bond III stainer is fully automated Immunohistochemical and In Situ Hybridization (IHC and ISH stainer) (Photo courtesy of Leica Biosystems).

Mismatch Repair/Microsatellite Instability Evaluated Using Cytology Effusion Specimens

DNA mismatch repair (MMR) status is routinely assessed in colorectal and endometrial carcinoma as a method of cancer prevention, surveillance in patients with Lynch syndrome and their families, and for... Read more

Industry

view channel
Image: BioProfile FLEX2 Cell Culture Analyzer (Photo courtesy of Nova Biomedical)

Nova Biomedical Adds Sample Retain Collector to BioProfile FLEX2 Cell Culture Analyzer

Nova Biomedical (Waltham, MA, USA) has added a Sample Retain Collector (SRC) for its BioProfile FLEX2 automated cell culture analyzer which measures up to 16 tests including pH, gases, metabolites, osmolality,... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.